<qa>  What is the objective evidence of progression of the lesion by RECIST 1.1 between theSubjects who have received radiotherapy to tumor lesions that would be chosen as target lesions measurable disease within 4 weeks before the start of treatment, except if there is objective evidence of progression of the lesion by RECIST 1.1 between the 